Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Celgene's Otezla Gains Positive Recommendation from NICE
by Zacks Equity Research
Celgene Corporation (CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla.
Juno Gets Breakthrough Therapy Status for Lymphoma Drug
by Zacks Equity Research
Juno Therapeutics, Inc. (JUNO) and partner Celgene Corporation (CELG), announced that the FDA has granted Breakthrough Therapy designation to their investigational candidate, JCAR017.
Celgene (CELG) Otezla Approved in Japan for Two Indications
by Zacks Equity Research
Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.
Agios Stops Development of PKR Activator AG-519, Stock Falls
by Zacks Equity Research
Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
3 Great Stocks to Beat the Biotech Blues
by Arpita Dutt
Are you on the lookout for some good biotech stocks this month? Here are three that warrant a look.
Corcept Korlym Positive in Phase I/II Breast Cancer Study
by Zacks Equity Research
Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.
Stock Market News for December 09, 2016
by Zacks Equity Research
Markets finished at record highs again on Thursday following ECB's announcement about trimming bond-buying volume and the continuing Trump induced rally.
Stock Market News for December 08, 2016
by Zacks Equity Research
The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
by Arpita Dutt
This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.
Juno Reports Positive Phase I Study Data on Lymphoma Drug
by Zacks Equity Research
Juno Therapeutics, Inc. (JUNO) announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients non-Hodgkin lymphoma (NHL).
Acceleron, Celgene Present Myelodysplastic Syndromes Data
by Zacks Equity Research
Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.
bluebird Stock Up on Positive Interim Multiple Myeloma Data
by Zacks Equity Research
bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.
Here's Why Bluebird Bio (BLUE) is Rallying Today
by Madeleine Johnson
On Thursday, shares of Bluebird Bio Inc. (BLUE) are rallying, up over 17% in midday trading after positive results came in for its experimental anti-BCMA CAR (chimeric antigen receptor) T-cell product candidate bb2121.
NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day
Celgene vs. Regeneron: Which Stock is a Better Pick?
by Arpita Dutt
Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
Fundamentals Remain Strong in the Pharma Sector
by Arpita Dutt
We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.
The Zacks Analyst Blog Highlights: Dow Chemical, Celgene, Ford, BB&T and Sony
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Dow Chemical, Celgene, Ford, BB&T and Sony
Top Research Reports for Celgene, Ford & Dow Chemical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Dow Chemical (DOW), Celgene (CELG), and Ford (F).
Top Research Reports for Amazon, Celgene & Chubb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Celgene (CELG) and Chubb (CB).
Stock Market News for July 07, 2016
by Zacks Equity Research
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
Stock Market News for May 10, 2016
by Zacks Equity Research
Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks
Stock Market News for April 12, 2016
by Zacks Equity Research
Benchmarks closed in the red on Monday following losses in healthcare and consumer staples stocks.
Stock Market News for March 16, 2016
by Zacks Equity Research
Benchmarks ended mostly in the red following losses in healthcare and biotech stocks. Further, continuing decline in oil prices also weighed on key U.S. indexes